Product Description
Mechanisms of Action: Cytochrome P450 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Austria | Bangladesh | Brazil | Canada | Chile | Colombia | Cyprus | Dominican Republic | Egypt | Finland | France | Germany | Greece | Hong Kong | India | Indonesia | Ireland | Italy | Korea | Lebanon | Mexico | Morocco | New Zealand | Pakistan | Peru | Philippines | Portugal | Spain | Taiwan | Turkey | Ukraine | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|